vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and RANGE RESOURCES CORP (RRC). Click either name above to swap in a different company.
RANGE RESOURCES CORP is the larger business by last-quarter revenue ($786.9M vs $622.0M, roughly 1.3× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 22.8%, a 11.7% gap on every dollar of revenue. On growth, RANGE RESOURCES CORP posted the faster year-over-year revenue change (18.0% vs 4.8%). Over the past eight quarters, RANGE RESOURCES CORP's revenue compounded faster (14.6% CAGR vs 4.6%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Range Resources Corporation is a natural gas exploration and production company, the headquartered is in Fort Worth, Texas. It operates in the Marcellus Formation, where it is the largest land owners.
RPRX vs RRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $786.9M |
| Net Profit | $214.2M | $179.1M |
| Gross Margin | — | 94.5% |
| Operating Margin | 62.4% | — |
| Net Margin | 34.4% | 22.8% |
| Revenue YoY | 4.8% | 18.0% |
| Net Profit YoY | 2.9% | 88.8% |
| EPS (diluted) | $0.49 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | $786.9M | ||
| Q3 25 | $609.3M | $655.3M | ||
| Q2 25 | $578.7M | $699.6M | ||
| Q1 25 | $568.2M | $846.3M | ||
| Q4 24 | $593.6M | $667.0M | ||
| Q3 24 | $564.7M | $567.9M | ||
| Q2 24 | $537.3M | $513.2M | ||
| Q1 24 | $568.0M | $598.8M |
| Q4 25 | $214.2M | $179.1M | ||
| Q3 25 | $288.2M | $144.3M | ||
| Q2 25 | $30.2M | $237.6M | ||
| Q1 25 | $238.3M | $97.1M | ||
| Q4 24 | $208.2M | $94.8M | ||
| Q3 24 | $544.0M | $50.7M | ||
| Q2 24 | $102.0M | $28.7M | ||
| Q1 24 | $4.8M | $92.1M |
| Q4 25 | — | 94.5% | ||
| Q3 25 | — | 92.5% | ||
| Q2 25 | — | 95.0% | ||
| Q1 25 | — | 93.1% | ||
| Q4 24 | — | 93.7% | ||
| Q3 24 | — | 94.3% | ||
| Q2 24 | — | 93.4% | ||
| Q1 24 | — | 94.7% |
| Q4 25 | 62.4% | — | ||
| Q3 25 | 70.1% | — | ||
| Q2 25 | 36.3% | — | ||
| Q1 25 | 94.0% | — | ||
| Q4 24 | 60.9% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 50.2% | — | ||
| Q1 24 | -13.0% | — |
| Q4 25 | 34.4% | 22.8% | ||
| Q3 25 | 47.3% | 22.0% | ||
| Q2 25 | 5.2% | 34.0% | ||
| Q1 25 | 41.9% | 11.5% | ||
| Q4 24 | 35.1% | 14.2% | ||
| Q3 24 | 96.3% | 8.9% | ||
| Q2 24 | 19.0% | 5.6% | ||
| Q1 24 | 0.8% | 15.4% |
| Q4 25 | $0.49 | $0.75 | ||
| Q3 25 | $0.67 | $0.60 | ||
| Q2 25 | $0.07 | $0.99 | ||
| Q1 25 | $0.55 | $0.40 | ||
| Q4 24 | $0.46 | $0.38 | ||
| Q3 24 | $1.21 | $0.21 | ||
| Q2 24 | $0.23 | $0.12 | ||
| Q1 24 | $0.01 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $204.0K |
| Total DebtLower is stronger | $9.0B | $1.2B |
| Stockholders' EquityBook value | $9.7B | $4.3B |
| Total Assets | $19.6B | $7.4B |
| Debt / EquityLower = less leverage | 0.92× | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | $204.0K | ||
| Q3 25 | $938.9M | $175.0K | ||
| Q2 25 | $631.9M | $134.0K | ||
| Q1 25 | $1.1B | $344.6M | ||
| Q4 24 | $929.0M | $304.5M | ||
| Q3 24 | $950.1M | $277.4M | ||
| Q2 24 | $1.8B | $251.1M | ||
| Q1 24 | $843.0M | $343.1M |
| Q4 25 | $9.0B | $1.2B | ||
| Q3 25 | $8.9B | $1.2B | ||
| Q2 25 | $8.0B | $1.2B | ||
| Q1 25 | $7.6B | $1.7B | ||
| Q4 24 | $7.6B | $1.7B | ||
| Q3 24 | $7.6B | $1.7B | ||
| Q2 24 | $7.6B | $1.7B | ||
| Q1 24 | $6.1B | $1.8B |
| Q4 25 | $9.7B | $4.3B | ||
| Q3 25 | $9.6B | $4.2B | ||
| Q2 25 | $9.5B | $4.1B | ||
| Q1 25 | $9.8B | $3.9B | ||
| Q4 24 | $10.3B | $3.9B | ||
| Q3 24 | $10.3B | $3.9B | ||
| Q2 24 | $9.8B | $3.9B | ||
| Q1 24 | $9.9B | $3.8B |
| Q4 25 | $19.6B | $7.4B | ||
| Q3 25 | $19.3B | $7.2B | ||
| Q2 25 | $18.3B | $7.1B | ||
| Q1 25 | $17.6B | $7.4B | ||
| Q4 24 | $18.2B | $7.3B | ||
| Q3 24 | $18.0B | $7.2B | ||
| Q2 24 | $17.7B | $7.3B | ||
| Q1 24 | $16.1B | $7.4B |
| Q4 25 | 0.92× | 0.28× | ||
| Q3 25 | 0.93× | 0.29× | ||
| Q2 25 | 0.84× | 0.29× | ||
| Q1 25 | 0.78× | 0.43× | ||
| Q4 24 | 0.74× | 0.43× | ||
| Q3 24 | 0.74× | 0.44× | ||
| Q2 24 | 0.78× | 0.44× | ||
| Q1 24 | 0.62× | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $257.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.86× | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | $257.5M | ||
| Q3 25 | $702.6M | $247.5M | ||
| Q2 25 | $364.0M | $336.2M | ||
| Q1 25 | $596.1M | $330.1M | ||
| Q4 24 | $742.5M | $217.9M | ||
| Q3 24 | $703.6M | $245.9M | ||
| Q2 24 | $658.2M | $148.8M | ||
| Q1 24 | $664.6M | $331.9M |
| Q4 25 | 3.86× | 1.44× | ||
| Q3 25 | 2.44× | 1.72× | ||
| Q2 25 | 12.06× | 1.42× | ||
| Q1 25 | 2.50× | 3.40× | ||
| Q4 24 | 3.57× | 2.30× | ||
| Q3 24 | 1.29× | 4.85× | ||
| Q2 24 | 6.45× | 5.18× | ||
| Q1 24 | 139.10× | 3.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
